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Molecular dockingAbstract Copper based metallo drugs were prepared and their antibacterial, antifungal, molecular
mechanism of [Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O complexes were investigated. The
[Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O were derived from the Schiff base alanine salicylalde-
hyde. [Cu(SAla)Phen]ÆH2O showed noteworthy antibacterial and antifungal activity than the
[Cu(SAla)bpy]ÆH2O and ligand alanine, salicylaldehyde. The [Cu(SAla)Phen]ÆH2O complex showed
signiﬁcant antibacterial activity against Salmonella typhi, Staphylococcus aureus, Salmonella paraty-
phi and the antifungal activity againstCandida albicans andCryptococcus neoformans in well diffusion
assay. Themode of action of copper (II) complex was analyzed byDNA cleavage activity and in silico
molecular docking. The present ﬁndings provide important insight into the molecular mechanism of
copper (II) complexes in susceptible bacterial and fungal pathogens. These results collectively support
the use of [Cu(SAla)Phen]ÆH2O complex as a suitable drug to treat bacterial and fungal infections.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Antimicrobial resistance is fast becoming a global concern
with rapid increase in multidrug resistant bacteria. To over-
come the alarming problem of microbial resistance to antibiot-
ics, the discovery of novel active compounds against new
targets is a matter of urgency. Many of the crude drugs, which
are sources of medicinal preparations, still originate from wild
growing material. This revival interest was generated by the
954 S. Chandraleka et al.discovery of the antibacterial, antifungal and anticancer activ-
ity of several metal complexes (Saha et al., 2009).
The medicinal application of metal complexes has been a
subject of great interest recently (Guo and Sadler, 2000). Apart
from the huge success of platinum based drugs, some other
metal compounds such as titanium and ruthenium complexes
have shown some potential for chemotherapy. The toxicity
of metallo drugs is problematic; therefore, it is proposed that
drugs based on essential metals may be less toxic, which has
led to the investigation of copper based drugs. Copper com-
plexes have indeed demonstrated a wide range of pharmaco-
logical activity such as Antibacterial (Gao et al., 2004;
Geraghty et al., 2000; Creaven et al., 2006), Antifungal
(White et al., 1998; Abu Salah, 1996; Kavanagh et al., 2004)
antiviral (Kaska et al., 1978; Ranford et al., 1993; West and
Owens, 1998), anticancer (Berners-Price et al., 1987;
Moubaraki et al., 1999; Kong et al., 2000) and anti-inﬂamma-
tory activity (Andrade et al., 2000). It was found that copper
complexes often demonstrate enhanced biological activity than
the parent ligand alone (Mohindru et al., 1983; Ainscough
et al., 1998).
Many drugs possess modiﬁed pharmacological and toxico-
logical properties when administered in the form of metallic
complexes. Probably the most widely studied cation in this
respect is Cu2+, since a host of low molecular weight copper
complexes have been proven beneﬁcial against several diseases
such as tuberculosis, rheumatoid, gastric ulcers, and cancers
(Sorenson, 1976; Brown et al., 1980; Ruiz et al., 1995). Twenty
natural amino acids comprise the building blocks of proteins,
which are chemical species indispensable to perform a huge
number of biological functions, as exempliﬁed by the role of
enzymes. From these 20 amino acids, eight are essential and can-
not be produced by the human body. Complexes of transition
metals with amino acids in proteins and peptides are utilized
in numerous biological processes, such as oxygen conveyer,
electron transfer and oxidation. In these processes, the enzy-
matic active site, which is very speciﬁc, forms complexes with
divalent metal ions (Vemrlinov et al., 2006). 1,10-Phenanthro-
line (1,10-phen), 2,20-bipyridine (2,20-bipy) and their substituted
derivatives, both in the metal-free state and as ligands coordi-
nated to transition metals, disturb the functioning of a wide
variety of biological systems. When the metal-free N, N-chelat-
ing bases are found to be bioactive it is usually assumed that the
sequestering of trace metals is involved, and that the resulting
metal complexes are the actual active species.
Copper complexes of 1,10-phenanthroline and its deriva-
tives are able to target DNA and have been used as DNA
nuclease as foot printing agents (Sigman, 1990; Mazumder
et al., 1993; Sigman et al., 1993; Mahadevan and
Palaniandavar, 1998). Modiﬁcation of 1,10-phenanthroline
copper complex has resulted in the discovery of a series of anti-
cancer agents casiopeinas (Ruiz-Ramı´rez et al., 1993, 1995),and one of the complexes has been shown to induce apoptosis
of murine leukemia cell lines (Vizcaya-Ruiz et al., 2000). The
casiopeinas are a group of Cu2+ mixed-ligand antineoplastic
agents which contain 1,10-phenanthroline or 2,20-bipyridine
and other bidentate ligands. These compounds exhibit cytotox-
icity, genotoxicity, and antitumor effects, but their mode of
action is presently unknown (Shi et al., 2010).
A number of reports have appeared in the literature high-
lighting the use of transition metal complexes as both antibac-
terial and antifungal agents (Geraghty et al., 1999). The in vitro
antibacterial action of 1,10-phenanthroline has been demon-
strated on several species of bacteria. Phenanthroline metal
complexes can be bacteriostatic and bacteriocidal toward
many Gram-positive bacteria they are relatively ineffective
against Gram-negative organisms.
Metal based drugs represent a novel group of antifungal
agents with potential applications for the control of fungal
infections. 1,10-Phenanthroline and substituted derivatives,
both in the metal-free state and as ligands coordinated to tran-
sition metals, disturb the functioning of a wide variety of bio-
logical systems (Butler et al., 1969).
DNA binding and cleavage are two critical events for gene
mutation and carcinogenesis in biological systems. Metal com-
plexes have demonstrated a natural DNA-targeting aptitude
and have been studied extensively (Boerner and Zaleski,
2005). In addition to this, the interaction of these Schiff base
metal complexes with DNA has been extensively studied in
the past decades. Due to the site speciﬁc binding properties
and many fold applications in cancer therapy, these coordina-
tion compounds were suitable candidates as DNA secondary
structure probes, photo cleavers, and antitumor drugs (Chan
and Wong, 1995; Pratviel et al., 1998; Liang et al., 2004).
One of the most effective metal-based nucleases is the copper
complex of 1,10-phenanthroline which has been extensively
used for mapping protein and drug binding sites on DNA as
well as for studying DNA structure (Sigman et al., 1993).
DNA degradation by a 1,10-phenanthroline-Cu (II) complex
requires both a reducing agent and molecular oxygen.
Docking is frequently used to predict the binding orienta-
tion of small molecule drug candidates to their protein targets
in order to in turn predict the afﬁnity and activity of the small
molecule. Hence docking plays an important role in the
rational design of drugs. The cytochrome P450 superfamily
(ofﬁcially abbreviated as CYP) is a large and diverse group
of enzymes. The function of most CYP enzymes is to catalyze
the oxidation of organic substances. The substrates of CYP
enzymes include metabolic intermediates such as lipids and ste-
roidal hormones, as well as xenobiotic substances such as
drugs and other toxic chemicals. CYP 51 shows structural rela-
tionships with P450 enzymes involved in the synthesis of poly-
ketide antibiotics. CYP 51 inhibitors block ergosterol synthesis
at one or more sites with the accumulation of 14a-methyl ste-
rol. Depletion of ergosteroland accumulation of sterol precur-
sors, results in the formation of a plasma membrane with
altered structure and function of several membrane bound
enzymes. For this purpose, the docking of Cu (II) metal com-
plex into the active site of the model was explored. The struc-
turally and functionally important residues identiﬁed allowed
for a better understanding of the structure–function relation-
ships of the enzyme. The modes of the enzymes substrate
and enzyme-inhibitor interactions would be useful in develop-
ing more potent antifungal and antibacterial drugs.
Antimicrobial mechanism of copper (II) 1,10-phenanthroline 955The literature review reveals that the molecular mechanism
of copper (II) phenanthroline and copper (II) bipyridyl com-
plex is very minimum. In the present study, we report the syn-
thesis of copper (II) metal complex by using 1,10-
phenanthroline and 2,20-bipyridyl in the presence of alanine
salicylaldehyde as a ligand and the antibacterial and antifungal
activity against the selected bacterial and fungal pathogens to
investigate the molecular mechanism of copper (II) complexes
on selected microbial pathogens using DNA cleavage activity
and in silico molecular docking.
2. Experimental
2.1. Materials
All chemicals used in the synthesis of the copper complex were
analytical grade while L-alanine, salicylaldehyde, copper (II)
acetate monohydrate, 1,10-phenanthroline and 2,20-bipyridyl
were obtained fromMerck Specialities Private Limited. Micro-
biological culture media, agarose and ethidium bromide were
obtained from Himedia Laboratories Private Limited.
2.2. Synthesis of ligand
To a solution of alanine (1 g) in water (10 ml) containing KOH
(0.63 g, 10 mmol) was added salicylaldehyde (1.37 g, 10 mmol)
in ethanol (10 ml). The yellow solution was stirred for 30 min
at room temperature prior to cooling in an ice bath. The inter-
mediate Schiff base that had formed was reduced with an
excess of sodium borohydride (0.51 g, 10 mmol) in water
(5 ml) containing a few drops of sodium hydroxide solution.
The yellow color slowly discharged, and after 10 min the solu-
tion was acidiﬁed with concentrated HCl to a pH of 3.5–5.0.
The resulting solid was ﬁltered off, washed with ethanol and
then diethyl ether, dried, and recrystallized from water/ethanol
(1:1).
2.3. Synthesis of copper metal complex
To the royal blue solution formed from copper(II) acetate
monohydrate (200 mg, 1 mmol) in ethanol (15 ml) and 1,10-
phenanthroline (180 mg, 1 mmol) in ethanol (10 ml) was added
a ﬁltered solution of H2SAla (200 mg, 1 mmol) in water (10 ml)
with KOH (1 ml, 1 M). The dark green solutions were stirred
for 2 h and then ﬁltered and left for several days, after which
crystalline solids had formed that were ﬁltered off, washed
with ethanol, and dried in a desiccator for few more days.
Finally it produces the copper(II) alanine salicylaldehyde
1,10-phenanthroline complex.
As the general procedure for preparing binary complexes
was the same, 2,20-bipyridyl was added instead of 1,10-phenan-
throline for the synthesis of copper(II) alanine salicylaldehyde
2,20-bipyridyl complex.
2.4. Antimicrobial activity of copper (II) metal complex
2.4.1. Culture collection
Bacterial and fungal cultures such as Salmonella typhi, Salmo-
nella paratyphi, Staphylococcus aureus, Escherichia coli, Enter-
obacter sp, Klebsiella pneumoniae, Pseudomonas aeruginosa,Proteus sp, Aspergillus niger, Aspergillus ﬂavus,Mucor sp, Pen-
icillum sp, Candida albicans, Cryptococcus neoformans, Fusar-
ium oxysporum, Pythium aphanidermatum and Alternaria
alternata were obtained from the Germplasm, Department of
Microbiology, Bharathidasan University, Tiruchirappalli. Cul-
tures were routinely subcultured every 4–6 weeks.
2.4.2. Antimicrobial activity
The in vitro antimicrobial screening effects of the copper (II)
metal complex were tested against Salmonella typhi, Salmo-
nella paratyphi, Staphylococcus aureus, E. coli, Enterobacter
sp, Klebsiella pneumoniae, P. aeruginosa and Proteus sp, by
the well diffusion method, using nutrient agar as the medium.
The antifungal activities of the test compounds were evaluated
by the well diffusion method against A. niger, A. ﬂavus, Mucor
sp, Penicillum sp, Candida. albicans, Cryptococcus neoformans,
F. oxysporum, P. aphanidermatum and A. alternata cultured on
potato dextrose agar as medium. The stock solution (100 mg/
ml) was prepared by dissolving the compounds in aqueous and
the solutions were serially diluted in different concentration
(400, 600, 800 and 1000 lg) in order to ﬁnd the MIC values.
In a typical procedure a well was made on the agar medium
inoculated with microorganisms. The well (6 mm diameter)
was ﬁlled with 30 ll of the test solution using a micropipette
and the plate was incubated, 24 h at 37 C for bacteria and
72 h for fungi at 28 C. During this period, the test solution
diffused and the growth of the inoculated microorganisms
was affected. The inhibition zone was developed, at which
the concentration was noted.
2.5. DNA cleavage analysis of copper metal complex
Based on the antimicrobial sensitivity pattern of copper (II)
complex, the following bacteria Salmonella typhi, Staphylococ-
cus aureus and fungi Candida albicans and Cryptococcus neo-
formans were justiﬁably chosen as suitable host to evaluate
the DNA cleavage test.
2.5.1. Isolation of DNA from the susceptible bacteria
The fresh bacterial culture (1.5 ml) was centrifuged at
12,000 rpm for 10 min to obtain the pellet and dissolved in
1 ml of lysis solution (0.05 m Tris HCl, 0.1 M NaCl, 0.05 M
EDTA, 2% SDS and b-mercaptoethanol). This mixture was
incubated at room temperature for 15–20 min. To this 100 ll
of proteinase K was added and incubated at 50 C for
45 min. After incubation the mixture was centrifuged at
10,000 rpm for 10 min. To the supernatant add equal volume
of chloroform and mix well. After 5 min centrifuge the mixture
at 8000 rpm for 8 min. The aqueous phase is transferred to a
new tube and added 800 ll of isopropanol. Then it was kept
in an icebath for 5 min. After that centrifuge at 10,000 rpm
for 10 min and discard the supernatant. To the pellet add
200 ll of 70% ethanol and keep it in ice for 5 min. Then the
reaction mixture was centrifuged at 10,000 rpm for 5 min.
Dry the pellet and dissolve in 50 ll of TE buffer and stored
at 4 C.
2.5.2. Isolation of DNA from the susceptible yeast
The fresh culture of Candida sp. was transferred to 5 ml of
SDB and incubated at 37 C for 24 h. Then, the culture pellet
956 S. Chandraleka et al.was obtained by centrifugation at 10,000 rpm for 10 min at
4 C. Two milliliter of the culture pellet was taken and washed
twice with 400 ll Solution I. Then to the pellet again 400 ll of
the Solution I was added and vortexed well. To that, 50 ll of
10% SDS was added and mixed by inverting and incubated
at 55 C for 30 min. Then 50 ll of proteinase K was added
and incubated for 1 h at 37 C. After that 500 ll of phe-
nol:chloroform was added and vortexed brieﬂy. The mixture
was centrifuged at 8000 rpm for 8 min. Then the aqueous
phase was taken and again phenol: chloroform step was car-
ried out. Then to the aqueous phase 500 ll of chloroform
was added and centrifuged at 8000 rpm for 8 min. Then the
aqueous phase was taken, to that 25 ll of 5 M NaCl and
1 ml of 99.99% chilled ethanol was added and incubated for
overnight at 20 C. Then the mixture was centrifuged at
13,000 rpm for 30 min at 4 C. Pellet was taken and 1 ml of
70% ethanol was added and centrifuged at 13,000 rpm for
15 min at 4 C. The above step was repeated again and the pel-
let was air dried and mixed with 50 ll of TE buffer and stored
at 20 C for further analysis.
2.5.3. DNA cleavage assay using agarose gel electrophoresis
Cleavage products were analyzed by agarose gel electrophore-
sis method. 4 ll of DNA sample was taken and mixed with 5 ll
of the [Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O complex
at different concentrations (25, 50, 75 and 100 lg) in separate
Eppendorff tube. The samples were incubated for 1 h at 37 C
and then 2 ll of bromophenol blue dye was mixed and loaded
carefully into the electrophoresis chamber wells along with the
control DNA. TAE buffer (4.84 g Tris base, pH 8.0, 0.5 M
EDTA/1 l) was used as a running buffer and ﬁnally loaded
on agarose gel and passed the constant 50 V of electricity for
around 30 min. Then the bands were observed in the gel con-
taining ethidium bromide under gel documentation system and
photographed to determine the extent of DNA cleavage and
the results are compared with the control.
2.6. Molecular mechanism of antimicrobial property of copper
(II) complex using molecular docking method
2.6.1. Ligand
The copper (II) complex [Cu(SAla)Phen]ÆH2O was chosen as
ligand for docking analysis. The 3D structure of the complex
was obtained using Chemsketch software from ACD Labs.
2.6.2. Target protein for docking analysis
CYP51 of Mycobacterium tuberculosis (14-a-sterol demethyl-
ase) was chosen as a target against the copper (II) complex
[Cu(SAla)Phen]ÆH2O. The 3D structure of CYP51 was
retrieved from the PDB data base (1EA1).
2.6.3. Molecular docking
The possible docking modes between the Cu (II) complex
[Cu(SAla)Phen]ÆH2O and the target enzyme (1EA1) were stud-
ied using Hex 6.3 docking software. The Hex 6.3 performs pro-
tein docking using Spherical Polar Fourier Correlations
(Ritche and Venkataraman, 2010). Hex 6.3 necessitates ligand
and the receptor as input in PDB format. The parameters used
for docking include: correlation type –shape only, FFT mode –3D, grid dimension –0.6, receptor range –180, ligand range –
180, twist range –360, distance range –40.
The mode of binding (H bond) between the Cu (II) complex
[Cu(SAla)Phen] with each receptor was visualized using Swiss
PDB viewer. The particular amino acid residue in 1EA1
responsible for hydrogen bond formation with the Cu (II)
complex [Cu(SAla)Phen] was also recognized.
2.6.4. Active site prediction
The active sites of the enzymes were predicted using CASTp
(computed atlas of surface topography of proteins) database
(http://sts.bioengr.uic.edu/castp/calculation.php) (Andrew
et al., 2003) This study was carried onto know the residue in
the target enzymes responsible for Cu(II) complex [Cu(SAla)-
Phen] binding was present in the active site or elsewhere. The
PDB code for the enzymes (1EA1) was given as input.
3. Results and discussion
3.1. Antimicrobial activity of copper (II) metal complex
The in vitro antimicrobial activity of the alanine salicylalde-
hyde ligand and their corresponding copper(II) complex
[Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O were evaluated
against Gram-negative bacterial pathogens such as Salmonella
typhi, Salmonella paratyphi, E. coli, Enterobacter sp, K. pneu-
moniae, P. aeruginosa and Proteus sp, Gram-positive pathogen
Staphylococcus aureus and the unicellular fungal pathogens
such as Candida albicans, Cryptococcus neoformans, ﬁlamen-
tous fungal pathogen A. niger, A. ﬂavus, Mucor sp, Penicillum
sp, Fusarium sp, A. alternata and P. aphanidermatum by well
diffusion method. The diameter of the zone of inhibition
(mm) was used to compare the antimicrobial activity of the test
compound with the commercial drug. Ampicillin and ampho-
tericin B were used as a reference drugs for antibacterial and
antifungal activity respectively. When compared to the refer-
ence drug copper (II) alanine salicylaldehyde 1,10-phenanthro-
line complex [Cu(SAla)Phen]ÆH2O and copper (II) alanine
salicylaldehyde 2,20-bipyridyl complex [Cu(SAla)bpy]ÆH2O
showed highest antimicrobial activity than free ligand. Two
copper (II) complexes produced highest antibacterial activity
against the Salmonella typhi, Salmonella paratyphi, and Staph-
ylococcus aureus (Table 1).
The maximum antifungal activity of the two copper (II)
complexes was reported against the Cryptococcus neoformans
and Candida albicans followed by Aspergillus niger, Aspergillus
ﬂavus, Penicillum sp and Mucor sp. These copper (II) com-
plexes were more active against the bacterial and fungal patho-
gens with increased concentration in the range of 400–1000 lg/
ml. The minimal inhibitory concentration (MIC) was mea-
sured using the highest zone of inhibition in the minimum level
and compared with the antibacterial and antifungal drug.
The antibacterial activity of the ligand and copper (II) com-
plexes was estimated based on the MIC values. Salmonella
typhi and Staphylococcus aureus was highly susceptible to test
copper (II) complexes but the ligand does not show any anti-
bacterial activity. The MIC value of [Cu(SAla)Phen]ÆH2O
and [Cu(SAla)bpy]ÆH2O against the test bacteria was consid-
ered as 400 lg/ml, which was compared with the commercial
drug ampicillin (Table 2, Fig. 1).
Table 1 Antibacterial activity of copper (II) complexes and reference drug.
S. No. Bacterial pathogens Zone of inhibition (mm)
Ligand H2SAla (lg/ml) [Cu(SAla)Phen]ÆH2O (lg/ml) [Cu(SAla)bpy]ÆH2O (lg/ml)
400 600 800 1000 400 600 800 1000 400 600 800 1000
1. Salmonella typhi –(10) –(19) –(21) –(25) 30(10) 30(19) 32(21) 33(25) 28(10) 30(19) 30(21) 33(25)
2. Salmonella paratyphi –(15) –(18) –(20) –(25) 19(15) 22(18) 28(20) 31(25) 7(15) 8(18) 9(20) 10(25)
3. Escherichia coli –(–) –(–) –(–) –(–) 11(–) 12(–) 19(–) 21(–) 7(–) 7(–) 8(–) 10(–)
4. Enterobacter aerogenes –(11) –(14) –(18) –(20) 18(11) 18(14) 18(18) 20(20) 7(11) 7(14) 10(18) 11(20)
5. Klebsiella pneumonia –(–) –(–) –(–) –(–) 15(–) 17(–) 20(–) 20(–) 8(–) 10(–) 12(–) 15(–)
6. Vibrio sp –(–) –(–) –(–) –(–) –(–) –(–) 8(–) 10(–) –(–) –(–) –(–) –(–)
7. Proteus sp –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–)
8. Staphylococcus aureus –(–) –(–) –(–) –(–) 28(–) 32(–) 32(–) 35(–) 26(–) 29(–) 31(–) 31(–)
9. Pseudomonas aeruginosa –(–) –(–) –(–) –(–) –(–) 7(–) –(–) –(–) –(–) –(–) –(–) –(–)
– absence of antibacterial activity, () activity of ampicillin reference drug was presented in parentheses.
Table 2 Antifungal activity of copper (II) complexes and reference drug.
S. No. Fungal pathogens Zone of inhibition (mm)
Ligand H2SAla (lg/ml) [Cu(SAla)Phen]ÆH2O (lg/ml) [Cu(SAla)bpy]ÆH2O (lg/ml)
400 600 800 1000 400 600 800 1000 400 600 800 1000
1. Aspergillus niger –(–) –(–) –(11) –(17) 11(–) 12(–) 13(11) 15(17) –(–) 8(–) 8(11) 10(17)
2. Aspergillus ﬂavus –(–) –(–) –(10) –(15) –(–) 10(–) 10(10) 12(15) –(–) –(–) –(10) –(15)
3. Mucor sp –(–) –(19) –(28) –(36) –(–) –(19) 10(28) 12(36) –(–) –(19) –(28) –(36)
4. Candida albicans –(–) –(15) –(18) –(25) –(–) –(15) –(18) 12(25) –(–) –(15) –(18) 13(25)
5. Cryptococcus neoformans –(–) –(20) –(27) –(32) 29(–) 30(20) 32(27) 32(32) –(–) –(20) –(27) –(32)
6. Fusarium sp –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–)
7. Alternaria alternata –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–)
8. Pythium aphanidermatum –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–) –(–)
9. Penicillum sp –(–) –(–) –(–) –(–) –(–) 10(–) 12(–) 14(–) –(–) –(–) –(–) –(–)
– absence of antifungal activity, () activity of amphotericin B reference drug was presented in parentheses.
Concentration of [Cu(SAla)Phen].H2O complex a - 400µg/ml, b - 600µg/ml,
c - 800µg/ml, d - 1000µg/ml 
a 
c 
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d 
e 
a
c
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d 
e
a 
c 
b 
d 
e 
a
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b 
d 
e 
Salmonella typhi 
Cryptococcus neoformans
Staphylococcus aureus 
Candida albicans 
Figure 1 Antimicrobial activity of [Cu(SAla)Phen]ÆH2O complex
against bacterial and fungal pathogens.
Antimicrobial mechanism of copper (II) 1,10-phenanthroline 957These ﬁndings reveal that the antibacterial activity is due to
the coordination of 1,10-phenanthroline with copper (II) ace-
tate monohydrate in the presence of salicylaldehyde and
alanine.
Antibacterial activity of N,N-dimethylbiguanide hydro-
chloride, [CuL0Cl] and [CuLCl] has been carried out against
Gram-positive and Gram-negative strains Staphylococcus aur-
eus, Bacillus pumilus, Salmonella and Escherichia coli using the
agar diffusion method. In the range of 10–1.25 mmol/l, the
compounds were more active against the test pathogens with
the increased concentration (Gao, 2007). The Cu (II) complex
displayed selective and effective antibacterial activity against
one Gram-positive spore-forming bacterium B. cereus,
Gram-positive bacteria S. aureus at 40–80 mg/ml, and poor
activity against other bacterial pathogens E. coli, M. luteus.
The Cu (II) complex had more antibacterial activity than
uncomplexed ligand and other complexes (Sonmez et al.,
2009).
In the present study, the susceptibility of the selected fungi
toward ligand and copper (II) complexes were screened by
measuring the size of the inhibition diameter. Commonly used
antifungal drugs amphotericin B were tested as positive con-
trols. The MIC value of the [Cu(SAla)Phen]ÆH2O complex
against the Cryptococcus neoformans was identiﬁed as
400 lg/ml. High concentration of [Cu(SAla)Phen]ÆH2O com-
plex was required for the anticandidal activity and 1000 lg/
ml was considered as the MIC value for Candida albicans. Ala-
DNA cleavage activity of Copper (II) complex using Salmonella typhi DNA 
Lane 1 – DNA alone, Lane 2 – 25µg[Cu(SAla)Phen].H2O,  Lane 3 –50µg [Cu(SAla)Phen].H2O, 
Lane 4 –75µg [Cu(SAla)Phen].H2O, Lane 5 –100µg [Cu(SAla)Phen].H2O,  
Lane 6 –25µg [Cu(SAla)bpy].H2O, Lane 7 –50µg [Cu(SAla)bpy].H2O,  
Lane 8 –75µg [Cu(SAla)bpy].H2O, Lane 9 –100µg [Cu(SAla)bpy].H2O. 
DNA cleavage activity of Copper(II) complex using Candida albicans DNA 
Lane 1 – DNA alone, 
Lane 2 –50µg [Cu(SAla)Phen].H2O,  
Lane 3 –75µg [Cu(SAla)Phen].H2O, 
Lane 4 –100µg [Cu(SAla)Phen].H2O, 
Lane 5 –50µg [Cu(SAla)bpy].H2O, 
Lane 6 –75µg [Cu(SAla)bpy].H2O,  
Lane 7 –100µg [Cu(SAla)bpy].H2O 
1 52 6 7 83 4 9 
1 52 6 73 4
Figure 2 DNA cleavage activity of copper (II) complex using susceptible bacterial Salmonella typhi and yeast Candida albicans DNA.
958 S. Chandraleka et al.nine salicylaldehyde ligand and [Cu(SAla)bpy]ÆH2O complex
does not show any antifungal activity.
Only the Cu(II) complex exhibited weak antifungal activity
(MICs, 640 mg/mL) against C. albicans, C. krusei and C. par-
apsilosis (Sonmez et al., 2009). Cu (II) complex with 4,6-
di(tert-butyl)-3-(2-hydroxyethylsulfanyl)-1,2-benzenediol is
more potent than the parent ligand toward A. niger and Fusar-
ium sp, P. lividum and Mucor sp. Cu (II) 2-[4,6-di(tert-butyl)-
2,3-dihydroxyphenylsulfanyl]acetic acid complex show higher
antifungal potency than the parent ligands toward P. lividum
and Mucor sp (Loginova et al., 2006).
The increased antimicrobial activity of the complexes can
be explained on the basis of the Overtone concept
(Anjaneyula and Rao, 1986) and the tweedy chelation theory
(Dharmaraj et al., 2001). According to the Overtone concept
of cell permeability, the lipid membrane surrounding the cell
favors the passage of only lipid-soluble materials, due to which
liposolubility is an important factor controlling the anti-micro-
bial activity. On chelation, the polarity of the metal ion will be
reduced to a greater extent due to the overlap of the ligand
orbital and partial sharing of the positive charge of the metalion with donor groups. Such complexation could enhance
the lipophilic character of the central metal atom, which sub-
sequently favors its permeation through the lipid layers of cel-
lular membrane, which inhibits the growth of bacteria.3.2. DNA cleavage analysis of copper metal complexes
3.2.1. DNA cleavage activity of copper metal complexes using
bacterial DNA
The synthetic copper compounds have been investigated on
their ability to promote nucleic acid cleavage, as well as receiv-
ing special attention for their action on DNA. Investigations
of the interaction of DNA with small molecule are basic work
in the design of new types of pharmaceutical molecules. Some
type of metal complexes interacted with DNA could induce the
breakage of DNA strand as shown by the gel electrophoresis
technique.
In the present study, the mode of action of the copper (II)
complex [Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O was
analyzed by DNA cleavage activity using the genomic DNA
3D structure of CYP51 from                         3D structure of [Cu(SAla)Phen].H2O 
Mycobacterium tuberculosis 
Docking of CYP51 and [Cu(SAla)Phen].H2O  
Figure 3 Molecular docking studies of [Cu(SAla)Phen]ÆH2O using Hex 6.3 software.
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highly susceptible to Cu(SAla)Phen]ÆH2O than
[Cu(SAla)bpy]ÆH2O complex which was conﬁrmed by antibac-
terial activity. Hence, the genomic DNA of the Salmonella
typhi was isolated and the OD value (260 and 280 nm) of the
DNA 1.8 indicates the purity of DNA without any protein
and RNA contamination. The isolated DNA (4 ll) was mixed
with the different concentration of (25, 50, 75 and 100 lg/5 ll)
[Cu(SAla)Phen]ÆH2O and [Cu(SAla)bpy]ÆH2O complex and
incubated at 37 C for 1 h (Fig. 2).
Lane 1 showed the isolated genomic DNA of the Salmo-
nella typhi without any treatment with complex. Lane 2
showed 25 lg of [Cu(SAla)Phen]ÆH2O complex treated DNA
which effectively cleave the DNA. Hence, the DNA band dis-
appeared in the agarose gel. Lanes 3, 4 and 5 showed the 50, 75
and 100 lg of [Cu(SAla)Phen]ÆH2O complex treated DNA,
respectively. While increasing the concentration of
[Cu(SAla)Phen]ÆH2O complex, the DNA quantity gradually
decreased and this ﬁndings indicates that the DNA cleaving
activity of [Cu(SAla)Phen]ÆH2O complex. The optimum con-
centration of [Cu(SAla)Phen]ÆH2O complex to cleave the Sal-
monella typhi DNA was found to be 25 lg.Lane 6 showed the 25 lg of [Cu(SAla)bpy]ÆH2O complex
treated DNA which was similar to Control DNA. It indicates
that the DNA is not affected by [Cu(SAla)bpy]ÆH2O complex
at low concentration. Lanes 7 and 8 showed that the 50 and
75 lg of [Cu(SAla)bpy]ÆH2O complex treated DNA, respec-
tively. The disappearance of DNA bands denotes the effective
cleavage of DNA. Lane 9 containing 100 lg of
[Cu(SAla)bpy]ÆH2O complex which highly degrades the
DNA. The degraded DNA could not show any band on the
agarose gel. Finally the optimal value for the DNA cleavage
of [Cu(SAla)bpy]ÆH2O complex was identiﬁed as 50 lg.
Many researchers investigated the nuclease activity of the
copper complexes using CT DNA by agarose gel electrophore-
sis in the presence of an oxidant. Raman and Raja (2007)
reported that the DNA cleavage activity of three new copper
complexes of mixed ligands derived from Schiff bases with
1,10-phenanthroline was monitored by agarose gel electropho-
resis using CT DNA. Arish and Nair (2010) showed that the
Cu (II) complexes cleave CT DNA more efﬁciently in the pres-
ence of an oxidant than the ligand, Co (II) and Ni (II) com-
plexes. Raman et al. (2008) concluded that the copper
complex cleaves DNA as compared to the control CT DNA
Table 3 Amino acid residues in the 59th pocket of CYP51.
Residue number Atom type Residue name
27 CG2 ILE
27 CD1 ILE
137 CA LEU
137 CD1 LEU
259 O HIS
259 CD2 HIS
259 CA HIS
262 OG SER
262 CB SER
263 C GLY
263 CA GLY
263 N GLY
264 N THR
264 CA THR
266 OG SER
267 CD1 TRP
267 NE1 TRP
316 O ARG
317 O LEU
318 NDI HIS
318 O HIS
318 C HIS
318 CA HIS
318 CB HIS
319 O PRO
319 CD PRO
320 CG PRO
320 CB PRO
320 CA PRO
322 CG2 ILE
350 CB ALA
350 O ALA
350 CA ALA
354 NH2 ARG
354 NE ARG
354 CD ARG
428 ND2 ASN
428 OD1 ASN
430 CE1 HIS
430 NE2 HIS
435 CB VAL
435 CG1 VAL
435 O VAL
436 OE1 GLN
436 CA GLN
437 N LEU
437 CB LEU
960 S. Chandraleka et al.while other Ni (II), Co (II) and Zn (II) complexes do not cleave
DNA in the presence of H2O2.
In our present study molecular mechanism of copper (II)
complexes was analyzed, hence the bacterial genomic DNA
was used instead of CT DNA for the DNA cleavage activity
in the absence of radical scavenger. The similar ﬁndings was
reported by Kurdekar et al. (2010) stated that the DNA cleav-
age efﬁciency of Co (II), Ni (II), Cu (II) and Zn (II) complexes.
The ligand and complexes were allowed to interact with the
E. coli DNA which illustrates the higher binding ability of
the complexes with E. coli DNA than the ligand.
3.2.2. DNA cleavage activity of copper metal complexes using
yeast DNA
In the present investigation, the effects of selected Copper (II)
complexes on the integrity of yeast DNA were evaluated and
compared with the control DNA free from copper (II) com-
plexes. Candida albicans was highly susceptible to
Cu(SAla)Phen]ÆH2O complex than the free ligand and
[Cu(SAla)bpy]ÆH2O complex which was conﬁrmed by anti-
fungal activity. Hence, the DNA was isolated from the Can-
dida albicans and the OD value (260 and 280 nm) of the
DNA 1.8 indicates the purity of DNA without any protein
and RNA contamination.
The isolated DNA (4 ll) was mixed with the different con-
centrations of (50, 75 and 100 lg/5 ll) [Cu(SAla)Phen]ÆH2O
and [Cu(SAla)bpy]ÆH2O complex and incubated at 37 C for
1 h (Fig. 2). Lane 1 showed the isolated genomic DNA of Can-
dida albicans without any treatment with complex. Lanes 2, 3
and 4 showed the 50, 75 and 100 lg/5 ll of [Cu(SAla)Phen]ÆH2-
O complex treated DNA, respectively. Lanes 5, 6 and 7
showed the 50, 75 and 100 lg/5 ll of [Cu(SAla)bpy]ÆH2O com-
plex treated DNA, respectively. The ﬁndings reveal that the
100 lg of [Cu(SAla)Phen]ÆH2O complex was required to cleave
the DNA of Candida albicans. [Cu(SAla)bpy]ÆH2O complex
treated DNA did not show any changes in the DNA band pat-
tern in the agarose gel electrophoresis. Hence, Candida albicans
was moderately resistant to [Cu(SAla)bpy]ÆH2O complex in
agar well diffusion method. The anticandidal activity ﬁndings
coincide with the DNA cleavage activity.
These results were supported by Patil et al. (2010) who
reported the representative Schiff base C12H11N3O3S and Co
(II), Ni (II) and Cu (II) complexes were studied for their
DNA cleavage activity by agarose gel electrophoresis method
against DNA of A. niger. It showed that the control DNA
alone does not show any apparent cleavage where as Schiff
base and its complexes shown the DNA cleavage.
The Cu (II) complex and metal-free phenanthroline seem to
have minimum effect on fungal DNA. This latter ﬁnding is
surprising since phen and copper (I)–phen complexes are
known to cleave DNA with the same preferences as micrococ-
cal nuclease (Jessee et al., 1982; Chen and Sigman, 1986).
The present ﬁndings concluded that the compound inhibits
the growth of the bacterial and fungal pathogen such as Sal-
monella typhi and Candida albicans by cleaving the genome
of susceptible microbial pathogens.
3.2.3. Analysis of molecular interaction of copper with
antibacterial target enzyme
It is well known that the initial target for any antibacterial and
antifungal drug would be the inhibition of cell membrane syn-thesis, 3D structure of CYP 51 (lanosterol 14-a-demethylase)
from Trypanosoma cruzi was chosen as drug target in the pres-
ent study. Till date the 3D structure for fungal CYP 51 is not
available. The lack of structure is because, the CYP 51 are
membrane components, making it difﬁcult to express in sufﬁ-
cient quantities for crystallization. Sterol 14-a-demethylases
(CYP51) family exist ubiquitously in animals, plants, ﬁshes,
lower eukaryotes such as slime mold, and a part of bacteria
(Aoyama, 2005). CYP51 are essential enzymes in sterol biosyn-
thesis in fungi and are vital drug targets in antifungal therapy.
Sterols found in all eukaryotic organisms are membrane com-
ponents which regulate the ﬂuidity and the permeability of
phospholipid bilayers (Schaller, 2003). New isoforms of
Hydrogen bond interaction between CYP 51 
and [Cu(SAla)Phen].H2O 
Hydrogen bond between ASN 428 residue of 
CYP 51 and O23, O30 of 
[Cu(SAla)Phen].H2O 
Prediction of active site in CYP51 using CASTp 
Figure 4 Molecular docking studies of [Cu(SAla)Phen]ÆH2O using Hex 6.3 software.
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biosynthesis and primary target of azole antimycotic drugs, are
found in pathogenic protists, Trypanosoma brucei (TB), T.
vivax, T. cruzi, and Leishmania major. The sequences share
approximately 80% amino acid identity and are approximately
25% identical to sterol 14-a-demethylases from other biologi-
cal kingdom. Cytochrome P450 14-a-sterol demethylases
(CYP51s) catalyze the oxidative removal of the 14-a-methyl
group of lanosterol and 24-methylene-24,25-dihydrolanosterol
in yeast and fungi, obtusifoliol in plants, and 24,25-dihydrol-
anosterol in mammals to give D14,15-desaturated intermedi-
ates in ergosterol (fungi), phytosterol (plants), and
cholesterol (animals) biosynthesis (Podust et al., 2007). The
cytochrome P450 14-a-demethylase, encoded by the ERG11
(CYP51) gene, is the primary target for the azole, polyenes
and allyamine class of antifungals. CYP 51 inhibitors block
ergosterol synthesis at one or more sites with the accumulation
of 14-a-methyl sterol (Ghannoum and Rice, 1999). Depletion
of ergosterol and accumulation of sterol precursors, results
in the formation of a plasma membrane with altered structure
and function of several membrane bound enzymes.
In this research, molecular docking between
[Cu(SAla)Phen]ÆH2O complex and the target enzyme 1EA1resulted in the prediction of appropriate binding site with E
value 183.15 kJ/mol. The hydrogen bond formation between
the oxygen atom of the ligand and nitrogen atom of ASN 428
residue of 1EA1 was visualized using swiss pdb viewer. The
docking studies evidence that [Cu(SAla)Phen]ÆH2O complex
has the ability to form H bonds with the target enzyme. This
indicates that the complex has very good afﬁnity on this
enzyme and forms stable complex, such that it disrupts the
enzyme function. The ligand has only one functional group
that acts as H bond acceptor and hence only one H bond is
formed between the ligand and the target (Fig. 3).
Active site is present in the target protein which facilitates
the binding of ligand with protein. CASTp identiﬁed one
active site for 1EA1. The Hydrogen bond is resulting from
the residue ASN428 of 1EA1 belongs to the 59th pocket of
protein (Table 3). The area of active site is found to be
396.5 m2 and the volume is 354.5 m3. The other residues in
the active site are also inferred (Fig. 4).
The present investigation reveals that, the H bond forming
residues of 1EA1present within its active sites. Hence the bind-
ing of [Cu(SAla)Phen]ÆH2O complex occurs in the active site of
the target enzyme leading to the disruption of function of
enzyme in bacterial and fungal ergosterol biosynthesis.
962 S. Chandraleka et al.These ﬁndings were carried out with the help of various in
silico pharmacology tools (Gomeni et al., 2001). In silico meth-
ods are helping to make decisions and simulate virtually every
facet of drug discovery, development and moving the pharma-
ceutical industry closer to engineering-based disciplines (Ekins
and Swaan, 2005).
4. Conclusion
Metal based drug represents a novel group of antimicrobial
agents with potential application for the control of bacterial
and fungal infections. Copper is an essential trace element
for many biological function and copper ion play an important
role in organism’s growth, cell division, protein synthesis and
the activity of metal enzymes. In the present study, mode of
action of copper based metallo drug on susceptible microbial
pathogen. Susceptible pathogens were identiﬁed by well diffu-
sion method and the molecular mechanism was investigated
using DNA cleavage analysis and molecular docking. The ﬁnd-
ing reveals that the satisfactory interaction of
[Cu(SAla)Phen]ÆH2O with the susceptible target enzyme lanos-
terol 14-a-demethylase (CYP51) of M. tuberculosis. Hence the
[Cu(SAla)Phen]ÆH2O complex is justiﬁably chosen to treat the
infections caused by Salmonella typhi, Staphylococcus aureus,
Salmonella paratyphi, Candida albicans and Cryptococcus neo-
formans. The result of the present investigation is extended to
develop new metallo drug as an alterative of current antibiotics
used to treat the drug resistant microbial pathogens.
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